Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (COMMUTE-a)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04861259
Recruitment Status : Recruiting
First Posted : April 27, 2021
Last Update Posted : May 27, 2021
Sponsor:
Collaborator:
Chugai Pharmaceutical
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.

Condition or disease Intervention/treatment Phase
Atypical Hemolytic Uremic Syndrome Drug: Crovalimab Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Estimated Study Start Date : June 21, 2021
Estimated Primary Completion Date : March 8, 2024
Estimated Study Completion Date : June 25, 2027


Arm Intervention/treatment
Experimental: Crovalimab
Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] C5 SNP (Single Nucleotide Polymorphism) Cohort - participants with documented C5 polymorphism.
Drug: Crovalimab
Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight >=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight >=100kg).




Primary Outcome Measures :
  1. Percentage of Participants with complete TMA response (cTMAr) [ Time Frame: Baseline up to Week 25 ]

Secondary Outcome Measures :
  1. Dialysis Requirement Status (Yes/No) [ Time Frame: Baseline up to Week 25 ]
  2. Observed Value in Estimated Glomerular Filtration Rate (eGFR) [ Time Frame: Up to 7 years ]
  3. Change in Estimated Glomerular Filtration Rate (eGFR) [ Time Frame: Up to 7 years ]
  4. Percentage of Participants with Change from Baseline in Chronic Kidney Disease (CKD) stage [ Time Frame: Up to 7 years ]
  5. Observed Value in Platelet Count [ Time Frame: Up to 7 years ]
  6. Observed Value in Lactate Dehydrogenase (LDH) (mg/dL) [ Time Frame: Up to 7 years ]
  7. Observed Value in Hemoglobin (mg/dL) [ Time Frame: Up to 7 years ]
  8. Change from Baseline in Platelet Count [ Time Frame: Up to 7 years ]
  9. Change from Baseline in Lactate Dehydrogenase (LDH) (mg/dL) [ Time Frame: Up to 7 years ]
  10. Change from Baseline in Hemoglobin (mg/dL) [ Time Frame: Up to 7 years ]
  11. Mean Change in Fatigue [ Time Frame: Up to 7 years ]
    Assessed by the FACIT-Fatigue Questionnaire.

  12. Percentage of Participants with Platelet Count >= LLN (Naive Cohort only) [ Time Frame: Baseline up to Week 25 ]
  13. Percentage of Participants with Normalization of LDH (i.e. =< ULN) (Naive Cohort only) [ Time Frame: Baseline up to Week 25 ]
  14. Percentage of Participants with >=25% decrease in Serum Creatinine (Naive Cohort only) [ Time Frame: Baseline up to Week 25 ]
  15. Time to complete TMA response (cTMAr) (Naive Cohort only) [ Time Frame: Baseline up to Week 25 ]
  16. Duration of complete TMA response (cTMAr) (Naive Cohort only) [ Time Frame: Baseline up to Week 25 ]
  17. Percentage of Participants with complete TMA response (cTMAr) (Naive Cohort only) [ Time Frame: Week 25 ]
  18. Percentage of Participants with maintained TMA control (mTMAc) (Switch Cohort only) [ Time Frame: Baseline through Week 25 ]
  19. Percentage of Participants with Adverse Events (AEs) [ Time Frame: Up to 7 years ]
  20. Percentage of Participants with Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension (including malignant renal hypertension) and Infections (including meningococcal meningitis) [ Time Frame: Up to 7 years ]
  21. Percentage of Participants with Adverse Events (AEs) leading to Study Drug Discontinuation [ Time Frame: Up to 7 years ]
  22. Percentage of Participants with clinical manifestations of Drug-Target-Drug Complex (DTDC) formation amongst those participants who switched to crovalimab treatment from eculizumab treatment or ravulizumab treatment [ Time Frame: Up to 7 years ]
  23. Serum Concentrations of Crovalimab over time [ Time Frame: Up to 7 years ]
  24. Percentage of Participants with Anti-Crovalimab Antibodies [ Time Frame: Up to 7 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body weight >= 40 kg at screening.
  • Vaccination against Neisseria meningitidis.
  • For participants receiving other therapies (e.g., immunosuppressants, corticosteroids, mTORi, or calcineurin inhibitors: stable dose for 28 days.
  • For female participants of childbearing potential: an agreement to remain abstinent or use contraception.
  • Participants with a prior kidney transplant are eligible if they have a known history of complement-mediated aHUS prior to the kidney transplant.
  • Evidence of TMA (for Naive Cohort only).
  • Onset of TMA =<28 days prior to first crovalimab administration (for Naive Cohort only).
  • Documented treatment with a C5 inhibitor (for Switch Cohort only).
  • Clinical evidence of response to a C5 inhibitor (for Switch Cohort only).
  • Known C5 polymorphism (for C5 SNP Cohort only).
  • Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP Cohort only).

Exclusion Criteria:

  • TMA associated with non-aHUS related renal disease.
  • Positive direct Coombs test.
  • Chronic dialysis and/or end stage renal disease.
  • Identified drug exposure-related TMA.
  • Presence or history of a condition that could trigger TMA, such as malignancy, organ transplant (other than kidney transplant) or autoimmune disease.
  • History of a kidney disease, other than aHUS.
  • History of Neisseria meningitidis infection within 6 months.
  • Known or suspected immune deficiency (e.g., history of frequent recurrent infections).
  • Positive HIV test.
  • Multi-system organ dysfunction or failure.
  • Recent IVIg treatment.
  • Pregnant or breastfeeding or intending to become pregnant.
  • Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within five half lives of that investigational product, whichever is greater.
  • Recent use of tranexamic acid.
  • Current or previous treatment with a complement inhibitor (for Naïve Cohort only).
  • Positive for Active Hepatitis B and C infection (HBV/HCV) (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
  • Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who recently received C5 inhibitor treatment).
  • Documented condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura (TTP), Shiga Toxin producing Escherichia Coli (STEC)-TMA, Pneumococcal HUS, TMA secondary to cobalamin C defect and TMA related to Diacylglycerol kinase ε (DGKE) nephropathy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04861259


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: BO42353 http://www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

Locations
Show Show 72 study locations
Sponsors and Collaborators
Hoffmann-La Roche
Chugai Pharmaceutical
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT04861259    
Other Study ID Numbers: BO42353
2020-002475-35 ( EudraCT Number )
First Posted: April 27, 2021    Key Record Dates
Last Update Posted: May 27, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Azotemia
Hemolytic-Uremic Syndrome
Atypical Hemolytic Uremic Syndrome
Syndrome
Hemolysis
Disease
Pathologic Processes
Uremia
Kidney Diseases
Urologic Diseases
Anemia, Hemolytic
Anemia
Hematologic Diseases
Thrombotic Microangiopathies
Thrombocytopenia
Blood Platelet Disorders